Retirement Systems of Alabama purchased a new position in shares of Cencora, Inc. (NYSE:COR – Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 36,544 shares of the company’s stock, valued at approximately $8,880,000.
Several other large investors also recently modified their holdings of the stock. Cairn Investment Group Inc. bought a new stake in Cencora in the 1st quarter valued at about $2,294,000. Hennion & Walsh Asset Management Inc. acquired a new position in shares of Cencora during the first quarter worth approximately $1,862,000. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH bought a new position in shares of Cencora in the 1st quarter worth $13,090,000. NBC Securities Inc. acquired a new stake in Cencora in the 1st quarter valued at $976,000. Finally, Park Avenue Securities LLC bought a new stake in Cencora during the 1st quarter valued at $2,114,000. Institutional investors and hedge funds own 97.52% of the company’s stock.
Cencora Stock Performance
COR traded up $0.18 during trading hours on Friday, hitting $222.68. The stock had a trading volume of 830,572 shares, compared to its average volume of 1,399,658. The stock has a market cap of $44.41 billion, a PE ratio of 24.34, a price-to-earnings-growth ratio of 1.55 and a beta of 0.45. The company has a quick ratio of 0.53, a current ratio of 0.89 and a debt-to-equity ratio of 3.41. The company’s fifty day simple moving average is $227.90 and its 200 day simple moving average is $228.39. Cencora, Inc. has a 1 year low of $171.65 and a 1 year high of $246.75.
Cencora Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were issued a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend was Thursday, May 9th. Cencora’s payout ratio is currently 22.32%.
Wall Street Analyst Weigh In
A number of research firms have recently weighed in on COR. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 2nd. Robert W. Baird lifted their price objective on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a report on Thursday, May 2nd. SVB Leerink reiterated an “outperform” rating and issued a $275.00 target price on shares of Cencora in a report on Thursday, June 27th. Finally, Citigroup boosted their price target on shares of Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $235.30.
View Our Latest Analysis on Cencora
Insiders Place Their Bets
In other news, EVP Gina Clark sold 1,874 shares of the firm’s stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $223.86, for a total transaction of $419,513.64. Following the transaction, the executive vice president now directly owns 13,284 shares of the company’s stock, valued at $2,973,756.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Cencora news, EVP Gina Clark sold 1,874 shares of the stock in a transaction on Friday, May 31st. The shares were sold at an average price of $223.86, for a total transaction of $419,513.64. Following the completion of the sale, the executive vice president now owns 13,284 shares of the company’s stock, valued at approximately $2,973,756.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Robert P. Mauch sold 57,564 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $235.09, for a total value of $13,532,720.76. Following the completion of the sale, the chief operating officer now directly owns 24,412 shares in the company, valued at $5,739,017.08. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,956,675 shares of company stock valued at $422,352,056. 15.80% of the stock is currently owned by corporate insiders.
Cencora Company Profile
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Stories
- Five stocks we like better than Cencora
- Stock Sentiment Analysis: How it Works
- Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Qualcomm Stock Continues to Rise in the Face of Negative News
- Which Wall Street Analysts are the Most Accurate?
- Top 3 Summer Stocks with Solid Growth Opportunities
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR – Free Report).
Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.